Herminia Argente-Escrig1, Ana Sánchez-Monteagudo2, Marina Frasquet3, Elvira Millet-Sancho4, Maria Dolores Martínez-Rubio5, Inmaculada Pitarch6, Miguel Tomás7, Carmen Espinós8, Vincenzo Lupo9, Teresa Sevilla10. 1. Health Research Institute Hospital La Fe (IIS La Fe), Department of Neurology of the Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain. Electronic address: argente_her@gva.es. 2. Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), 46012, Valencia, Spain. Electronic address: asanchez@cipf.es. 3. Health Research Institute Hospital La Fe (IIS La Fe), Department of Neurology of the Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain. Electronic address: frasquet_mar@gva.es. 4. Department of Clinical Neurophysiology of the Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain. Electronic address: millet_elv@gva.es. 5. Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), 46012, Valencia, Spain. Electronic address: mdmartinez@cipf.es. 6. Department of Paediatrics of the Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain. Electronic address: pitarch_inm@gva.es. 7. Department of Paediatrics of the Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain. Electronic address: tomas_mig@gva.es. 8. Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), 46012, Valencia, Spain; Department of Genomics and Translational Genetics, Centro de Investigación Príncipe Felipe (CIPF), Valencia 46012, Spain; INCLIVA & IIS-La Fe Rare Diseases Joint Units, Centro de Investigación Príncipe Felipe (CIPF), Valencia 46012, Spain. Electronic address: cespinos@cipf.es. 9. Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), 46012, Valencia, Spain; Department of Genomics and Translational Genetics, Centro de Investigación Príncipe Felipe (CIPF), Valencia 46012, Spain; INCLIVA & IIS-La Fe Rare Diseases Joint Units, Centro de Investigación Príncipe Felipe (CIPF), Valencia 46012, Spain. Electronic address: vlupo@cipf.es. 10. Health Research Institute Hospital La Fe (IIS La Fe), Department of Neurology of the Hospital Universitari i Politècnic La Fe, 46026, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain; Department of Medicine, School of Medicine, University of Valencia, 46010, Valencia, Spain. Electronic address: sevilla_ter@gva.es.
Abstract
BACKGROUND: Mutations in the FGD4 gene cause an autosomal recessive demyelinating peripheral neuropathy referred to as CMT4H, characterized by its onset in infancy or early-childhood and its slow progression. METHODS: The clinical and genetic status of two patients with CMT4H was studied, performing genetic testing with a panel of genes and analysing FGD4 mRNA expression by quantitative PCR. RESULTS: Two novel FGD4 variants (c.514delG and c.2211dupA) were identified in two mildly affected Spanish siblings with CMT4H, and with disease onset in late adolescence/adulthood (one of them remaining asymptomatic at 20). On examination, foot deformity was observed without weakness or sensory involvement, and in the muscles of the lower extremities magnetic resonance imaging showed no fat replacement. Further analysis of FGD4 expression in peripheral blood suggested that neither mutation affected splicing, nor did they affect the dosage of FGD4 mRNA (compared to a healthy control). It was predicted that each allele would produce a truncated protein, p.Ala172Glnfs*28 (c.514delG) and p.Ala738Serfs*5 (c.2211dupA), the latter containing all the functional domains of the native protein. CONCLUSIONS: The conservation of functional domains in the proteins produced from the FGD4 gene of two patients with CMT4H, could explain both the milder phenotype and the later disease onset in these patients. These results expand the clinical and mutational spectrum of FGD4-related peripheral neuropathies.
BACKGROUND: Mutations in the FGD4 gene cause an autosomal recessive demyelinating peripheral neuropathy referred to as CMT4H, characterized by its onset in infancy or early-childhood and its slow progression. METHODS: The clinical and genetic status of two patients with CMT4H was studied, performing genetic testing with a panel of genes and analysing FGD4 mRNA expression by quantitative PCR. RESULTS: Two novel FGD4 variants (c.514delG and c.2211dupA) were identified in two mildly affected Spanish siblings with CMT4H, and with disease onset in late adolescence/adulthood (one of them remaining asymptomatic at 20). On examination, foot deformity was observed without weakness or sensory involvement, and in the muscles of the lower extremities magnetic resonance imaging showed no fat replacement. Further analysis of FGD4 expression in peripheral blood suggested that neither mutation affected splicing, nor did they affect the dosage of FGD4 mRNA (compared to a healthy control). It was predicted that each allele would produce a truncated protein, p.Ala172Glnfs*28 (c.514delG) and p.Ala738Serfs*5 (c.2211dupA), the latter containing all the functional domains of the native protein. CONCLUSIONS: The conservation of functional domains in the proteins produced from the FGD4 gene of two patients with CMT4H, could explain both the milder phenotype and the later disease onset in these patients. These results expand the clinical and mutational spectrum of FGD4-related peripheral neuropathies.
Authors: Mirjam E van de Velde; Aniek Uittenboogaard; Wenjian Yang; Erik Bonten; Cheng Cheng; Deqing Pei; Marleen H van den Berg; Inge M van der Sluis; Cor van den Bos; Floor C H Abbink; Marry M van den Heuvel-Eibrink; Heidi Segers; Christophe Chantrain; Jutte van der Werff Ten Bosch; Leen Willems; William E Evans; Gertjan J L Kaspers Journal: Cancers (Basel) Date: 2022-07-19 Impact factor: 6.575